Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IMM040811 plus IMM092 in advanced solid tumors
CTR20262182Phase 2Active
- Sponsor
- ImmuneArk
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM040811, IMM092 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by ImmuneArk. Started Jun 2026; status: active.
02
Drugs
IMM040811IMM092
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262182.